Related Experiment Video
Updated: Mar 13, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment
Luca Antonioli1, Corrado Blandizzi2, Fabio Malavasi3
1Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; Department of Surgery and Center for Immunity and Inflammation, Rutgers-New Jersey Medical School, Newark, NJ, USA.
Abstract:
The ecto-5'-nucleotidase/CD73 enzyme plays a pivotal role in generating an adenosine-enriched immunosuppressed and pro-angiogenic niche supporting cancer development. The targeting of CD73 leads to reorganization of tumor microenvironment, shaping the phenotype of the infiltrating T cells. The development of CD73 monoclonal antibodies offers a promising new avenue for antineoplastic treatment.
Related Concept Videos
Tumor Immunotherapy
The Tumor Microenvironment
The Tumor Microenvironment

